Joanne Lannigan

Joanne Lannigan

Auto-generated profile, based on publicly available information

Joanne Lannigan

Flow Cytometry Support Services, LLC Alexandria Virginia USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2015 in Cytometry Part A
Verified
Journal Article
Closed access
PDF file
UEUta Erdbrügger
Uta Erdbrügger
JLJoanne Lannigan
Joanne Lannigan

5 June 2014 in Cytometry Part A
Verified
Journal Article
Open access
PDF file
UEUta Erdbrügger
Uta Erdbrügger
CRChristine K. Rudy
Christine K. Rudy
MEMark E. Etter
Mark E. Etter
KDKelly A. Dryden
Kelly A. Dryden
MYMark Yeager
Mark Yeager
JLJoanne Lannigan
Joanne Lannigan
Microparticles (MPs) are submicron vesicles released from cell membranes in response to activation, cell injury, or apoptosis. The clinical importance of MPs has become increasingly recognized, although no standardized method exists for their measurement. Flow cytometry (FCM) is the most commonly used technique, however, because of the small size of MPs, and the limitations of current FCM instrumentation, accurate identification is compromised by this methodology. We decided to investigate whether the use of FCM combined with imaging, such as is possible with the ImagestreamX imaging FC (ISX), would be a more sensitive approach to characterizing MPs. Combining FCM with imaging eliminates some of the limitations demonstrated by conventional FCM, whereas also providing morphological confirmation and the ability to distinguish true single events from aggregates and cell debris. The detection limit of standard nonspecialized FCM is suboptimal when compared to ISX. Evaluating MPs below 0.200 µm and sizing remain a challenge as some MPs remain below the detection limit of ISX. Standardized calibrators, that more closely reflect the physical characteristics of MPs, need further development. © 2014 International Society for Advancement of Cytometry

16 July 2009 in Blood
Verified
Journal Article
Open access
PDF file
KWKori L. Wallace
Kori L. Wallace
MMMelissa A. Marshall
Melissa A. Marshall
SRSusan I. Ramos
Susan I. Ramos
JLJoanne A. Lannigan
Joanne A. Lannigan
JFJoshua J. Field
Joshua J. Field
JLJoel Linden
Joel Linden
Ischemia-reperfusion injury (IRI) triggers an inflammatory cascade that is initiated by the activation of CD1d-restricted iNKT cells. In sickle cell disease (SCD), misshapen erythrocytes evoke repeated transient bouts of microvascular IRI. Compared with C57BL/6 controls, NY1DD mice have more numerous and activated (CD69+, interferon-γ+ [IFN-γ+]) lung, liver, and spleen iNKT cells that are hyperresponsive to hypoxia/reoxygenation. NY1DD mice have increased pulmonary levels of IFN-γ, IFN-γ–inducible chemokines (CXCL9, CXCL10), and elevated numbers of lymphocytes expressing the chemokine receptor CXCR3. Treating NY1DD mice with anti-CD1d antibody to inhibit iNKT cell activation reverses baseline pulmonary dysfunction manifested as elevated vascular permeability, decreased arterial oxygen saturation, and increased numbers of activated leukocytes. Anti-CD1d antibodies decrease pulmonary levels of IFN-γ and CXCR3 chemokines. Neutralization of CXCR3 receptors ameliorates pulmonary dysfunction. Crossing NY1DD to lymphocyte-deficient Rag1−/− mice decreases pulmonary dysfunction. This is counteracted by the adoptive transfer of 1 million NKT cells. Like mice, people with SCD have increased numbers of activated circulating iNKT cells expressing CXCR3. Together, these data indicate that iNKT cells play a pivotal role in sustaining inflammation in SCD mice by a pathway involving IFN-γ and production of chemotactic CXCR3 chemokines and that this mechanism may translate to human disease.

1 March 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KRKelly B. Reilly
Kelly B. Reilly
SSSuseela Srinivasan
Suseela Srinivasan
MHMelissa E. Hatley
Melissa E. Hatley
MPMary Kim Patricia
Mary Kim Patricia
JLJoanne Lannigan
Joanne Lannigan
CHCatherine C. Hedrick
Catherine C. Hedrick
We have shown that the 12/15-lipoxygenase (12/15-LO) product 12S-hydroxyeicosatetraenoic acid increases monocyte adhesion to human endothelial cells (EC) in vitro. Recent studies have implicated 12/15-LO in mediating atherosclerosis in mice. We generated transgenic mice on a C57BL/6J (B6) background that modestly overexpressed the murine 12/15-LO gene (designated LOTG). LOTG mice had 2.5-fold elevations in levels of 12S-hydroxyeicosatetraenoic acid and a 2-fold increase in expression of 12/15-LO protein in vivo. These mice developed spontaneous aortic fatty streak lesions on a chow diet. Thus, we examined effects of 12/15-LO expression on early events leading to atherosclerosis in these mice. We found that, under basal unstimulated conditions, LOTG EC bound more monocytes than B6 control EC (18 ± 2 versus 7 ± 1 monocytes/field, respectively; p < 0.0001). Inhibition of 12/15-LO activity in LOTG EC using a 12/15-LO ribozyme completely blocked monocyte adhesion in LOTG mice. Thus, 12/15-LO activity is required for monocyte/EC adhesion in the vessel wall. Expression of ICAM-1 in aortic endothelia of LOTG mice was increased severalfold. VCAM-1 expression was not changed. In a series of blocking studies, antibodies to α4 and β2 integrins in WEHI monocytes blocked monocyte adhesion to both LOTG and B6 control EC. Inhibition of ICAM-1, VCAM-1, and connecting segment-1 fibronectin in EC significantly reduced adhesion of WEHI monocytes to LOTG EC. In summary, these data indicate that EC from LOTG mice are “pre-activated” to bind monocytes. Monocyte adhesion in LOTG mice is mediated through β2 integrin and ICAM-1 interactions as well as through VLA-4 and connecting segment-1 fibronectin/VCAM-1 interactions. Thus, 12/15-LO mediates monocyte/EC interactions in the vessel wall in atherogenesis at least in part through molecular regulation of expression of endothelial adhesion molecules.

1 January 2017 in Methods
Verified
Journal Article
Closed access
JLJoanne Lannigan
Joanne Lannigan
UEUta Erdbruegger
Uta Erdbruegger

12 July 2010 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
CRC Edward Rose
C Edward Rose
JLJoanne A Lannigan
Joanne A Lannigan
PKPaul Kim
Paul Kim
JLJames J Lee
James J Lee
SFShu Man Fu
Shu Man Fu
SSSun-Sang J Sung
Sun-Sang J Sung